IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0264123.html
   My bibliography  Save this article

Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy

Author

Listed:
  • Paolo Angelo Cortesi
  • Ippazio Cosimo Antonazzo
  • Claudio Gasperini
  • Mihaela Nica
  • Daniela Ritrovato
  • Lorenzo Giovanni Mantovani

Abstract

Background: Siponimod is an effective treatment for patients with secondary progressive multiple sclerosis (SPMS), with active disease evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, however there is a need to evaluate its economic value and sustainability compared to other disease modifying-therapies (DMTs). Objective: To estimate the siponimod cost-effectiveness profile and its relative budget impact compared with other DMTs, by using the Italian National Healthcare System perspective. Methods: We performed: 1) a cost-effectiveness analysis (CEA) vs interferon beta-1b using an analytical Markov model and a life time-horizon, and 2) a budget impact analysis by using 3-years time-horizon. The results were reported as incremental cost-effectiveness ratio (ICER) and net-monetary benefit (NMB) for CEA, using a willingness to pay threshold of €40,000 per QALY gained, and as difference in the overall budget (Euro) between the scenario with and without siponimod for budget impact. Results: In the base case scenario siponimod resulted cost-effective compared with interferon beta-1b 28,891€ per QALY. Overall, the market access of siponimod was associated to an increased budget of about 3€ millions (+0.9%) in the next 3 years simulated. Conclusion: Compared to interferon beta-1b, siponimod seems to be cost-effective in SPMS patients and sustainable, with less than 1% overall budget increased in the next 3 years. Future studies need to confirm our results in the real word setting and in other countries.

Suggested Citation

  • Paolo Angelo Cortesi & Ippazio Cosimo Antonazzo & Claudio Gasperini & Mihaela Nica & Daniela Ritrovato & Lorenzo Giovanni Mantovani, 2022. "Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy," PLOS ONE, Public Library of Science, vol. 17(3), pages 1-12, March.
    • Handle: RePEc:plo:pone00:0264123
    DOI: 10.1371/journal.pone.0264123
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0264123
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0264123&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0264123?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Gisela Kobelt, 2006. "Costs and quality of life for patients with multiple sclerosis in Belgium," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 24-33, July.
    2. Gisela Kobelt, 2006. "Costs and quality of life for patients with multiple sclerosis in Belgium," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 24-33, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Visintin, Erica & Tinelli, Michela & Kanavos, Panos, 2019. "Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries," Health Policy, Elsevier, vol. 123(2), pages 118-129.
    2. B. Svendsen & N. Grytten & L. Bø & H. Aarseth & T. Smedal & K-M. Myhr, 2018. "The economic impact of multiple sclerosis to the patients and their families in Norway," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(9), pages 1243-1257, December.
    3. Hanna Gyllensten & Michael Wiberg & Kristina Alexanderson & Anders Norlund & Emilie Friberg & Jan Hillert & Olivia Ernstsson & Petter Tinghög, 2018. "Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(3), pages 435-446, April.
    4. Andrius Kavaliunas & Michael Wiberg & Petter Tinghög & Anna Glaser & Hanna Gyllensten & Kristina Alexanderson & Jan Hillert, 2015. "Earnings and Financial Compensation from Social Security Systems Correlate Strongly with Disability for Multiple Sclerosis Patients," PLOS ONE, Public Library of Science, vol. 10(12), pages 1-11, December.
    5. Hanne Marie Bøe Lunde & Wenche Telstad & Nina Grytten & Lars Kyte & Jan Aarseth & Kjell-Morten Myhr & Lars Bø, 2014. "Employment among Patients with Multiple Sclerosis-A Population Study," PLOS ONE, Public Library of Science, vol. 9(7), pages 1-7, July.
    6. Fernando Gracia & Mario Larreategui & Gaudencio Rodríguez & Aaron Benzadón & Michelle Ortiz & Divian Morales & Claudia Domínguez & Rosa Enith Carrillo & Carlos Valderrama & Luís Lizán & Blas Armién, 2018. "Costs of multiple sclerosis in Panama from societal, patient perspectives and health-related quality of life," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-12, October.
    7. Massimiliano Agovino & Maria Ferrara, 2022. "Disabilit?: diseguaglianza sociale ed economica. Un?analisi empirica e teorica," ECONOMIA PUBBLICA, FrancoAngeli Editore, vol. 2022(1), pages 11-42.
    8. Roxanne Cooksey & Muhammad J Husain & Sinead Brophy & Helen Davies & Muhammad A Rahman & Mark D Atkinson & Ceri J Phillips & Stefan Siebert, 2015. "The Cost of Ankylosing Spondylitis in the UK Using Linked Routine and Patient-Reported Survey Data," PLOS ONE, Public Library of Science, vol. 10(7), pages 1-17, July.
    9. A. J. Hawton & C. Green, 2016. "Multiple sclerosis: relapses, resource use, and costs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(7), pages 875-884, September.
    10. Olivia Ernstsson & Hanna Gyllensten & Kristina Alexanderson & Petter Tinghög & Emilie Friberg & Anders Norlund, 2016. "Cost of Illness of Multiple Sclerosis - A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(7), pages 1-25, July.
    11. Oliver Findling & Magdalena Baltisberger & Simon Jung & Christian P Kamm & Heinrich P Mattle & Johann Sellner, 2015. "Variables Related to Working Capability among Swiss Patients with Multiple Sclerosis—A Cohort Study," PLOS ONE, Public Library of Science, vol. 10(4), pages 1-9, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0264123. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.